Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitroreductase-based GDEPT.

William A Denny1

  • 1Auckland Cancer Society Research Centre, Faculty of Medical & Health Sciences, The University of Auckland, Private Bag 92019, Auckland, Auckland 1000, New Zealand.

Current Pharmaceutical Design
|June 8, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New antitubercular pretomanid analogues as potent payloads in polymeric micelles: Leveraging zebrafish assays to accelerate lead optimisation.

European journal of medicinal chemistry·2026
Same author

Advancing the antituberculosis activity of nitropicolinic acids and amides.

European journal of medicinal chemistry·2025
Same author

Development of fatty acid analogues with potent anabolic effects on bone in male mice.

Bone reports·2025
Same author

ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding.

The Biochemical journal·2024
Same author

Involvement of the tumour necrosis factor receptor system in glioblastoma cell death induced by palbociclib-heptamethine cyanine dye conjugate.

Cell communication and signaling : CCS·2024
Same author

Retraction: A New Class of Quinoline-Based DNA Hypomethylating Agents Reactivates Tumor Suppressor Genes by Blocking DNA Methyltransferase 1 Activity and Inducing Its Degradation.

Cancer research·2023

Nitroreductase enzymes, particularly from E. coli, are promising for gene-directed enzyme prodrug therapy (GDEPT). They activate prodrugs like CB 1954 into potent toxins, showing high selectivity and efficacy in preclinical models.

Area of Science:

  • Biochemistry
  • Enzymology
  • Cancer Therapy

Background:

  • Nitroreductases catalyze aromatic nitro group reduction to hydroxylamines, enabling efficient prodrug activation for targeted cancer therapy.
  • The E. coli nfsB gene product, an oxygen-insensitive flavin mononucleotide nitroreductase (NTR), is a key enzyme studied for GDEPT applications.
  • Several prodrug classes, including dinitroaziridinylbenzamides, dinitrobenzamide mustards, nitrobenzylcarbamates, and nitroindolines, have been developed for NTR-mediated GDEPT.

Purpose of the Study:

  • To review the development and application of nitroreductase enzymes in gene-directed enzyme prodrug therapy (GDEPT).
  • To highlight the efficacy and selectivity of NTR-activated prodrugs in preclinical cancer models.
  • To discuss the potential of NTR-GDEPT in clinical trials.

Main Methods:

Related Experiment Videos

  • Utilizing nitroreductase enzymes, specifically the E. coli nfsB gene product (NTR), to metabolize prodrugs.
  • Evaluating the selectivity and efficacy of various NTR-specific prodrugs, including CB 1954 and SN 23862, in cell lines and animal models.
  • Investigating the mechanism of prodrug activation and subsequent release of cytotoxic agents.

Main Results:

  • NTR demonstrates high selectivity (>1000-fold) for activating prodrugs in transfected cells.
  • CB 1954, a dinitroaziridinylbenzamide, shows potent and sustained inhibition of NTR-transfected tumors in mice and is in Phase I trials.
  • Related compounds like SN 23862 exhibit similar selectivity and enhanced bystander effects.
  • Nitrobenzyl carbamates and nitroindoline derivatives of cytotoxic agents are efficiently metabolized by NTR, releasing active drugs.

Conclusions:

  • Nitroreductase enzymes, particularly NTR, are highly effective for GDEPT, offering a powerful mechanism for targeted cancer cell killing.
  • Prodrug design is crucial for achieving high selectivity and efficacy, with CB 1954 and related compounds showing significant promise.
  • NTR-mediated GDEPT represents a viable strategy for cancer treatment, with ongoing clinical investigations supporting its therapeutic potential.